Pheburane
Payments companies reported to CMS as associated with Pheburane. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pheburane, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pheburane
These are the largest totals companies reported as associated with Pheburane. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Holly Bernal | Palo Alto, CA | Nurse Practitioner | $1,200.00 |
| Brandon Chalazan | Chicago, IL | Clinical Genetics (M.D.) | $69.94 |
| Ashton Aninzo | Austin, TX | Physician Assistant | $55.99 |
| Tarachandra Narumanchi | Philadelphia, PA | Clinical Genetics (M.D.) | $42.03 |
| Julie Boyd | Oklahoma City, OK | Nurse Practitioner | $39.29 |
| Yazmin Enchautegui Colon | Oklahoma City, OK | Clinical Genetics (M.D.) | $39.29 |
| Danielle Demarzo | Oklahoma City, OK | Clinical Genetics (M.D.) | $39.28 |
| Ashley Taylor | Oklahoma City, OK | Physician Assistant | $39.27 |
| Joshua Baker | Chicago, IL | Clinical Genetics (M.D.) | $26.13 |
| Mindy Li | Chicago, IL | Clinical Genetics (M.D.) | $26.13 |
Prescribed Pheburane?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.